Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.
about
Sirolimus and Everolimus Pathway: Reviewing Candidate Genes Influencing Their Intracellular EffectsSolid, non-skin, post-liver transplant tumors: Key role of lifestyle and immunosuppression managementNeoplastic disease after liver transplantation: Focus on de novo neoplasmsBurden of de novo malignancy in the liver transplant recipientDonor transmitted and de novo cancer after liver transplantation.From rapalogs to anti-aging formula.Skin cancer in organ transplant recipients: more than the immune system.Malignant and noninvasive skin tumours in renal transplant recipientsImmune profiling and cancer post transplantationEarly diagnosis and treatment of breast cancer in Japanese kidney transplant recipients: a single center experienceSirolimus effects on cancer incidence after kidney transplantation: a meta-analysis.Minimization vs tailoring: Where do we stand with personalized immunosuppression during renal transplantation in 2015?Management and prevention of post-transplant malignancies in kidney transplant recipientsInhibition of mTOR suppresses UVB-induced keratinocyte proliferation and survival.The benefits of cancer screening in kidney transplant recipients: a single-center experienceConversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotypeInhibition of Akt Enhances the Chemopreventive Effects of Topical Rapamycin in Mouse Skin.Prospective randomized trial of maintenance immunosuppression with rapid discontinuation of prednisone in adult kidney transplantation.Cancer in the transplant recipient.Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcomeEverolimus: preventing organ rejection in adult kidney transplant recipients.Management of non-melanoma skin cancer in immunocompromised solid organ transplant recipients.An evaluation of sirolimus in renal transplantation.The management of immunosuppression in patients with inflammatory bowel disease and cancer.Immunostimulatory activity of lifespan-extending agents.Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients.Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients.Epstein-Barr virus-associated smooth muscle tumors in children following solid organ transplantation: a review.Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients?Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?Renal cancer in kidney transplanted patients.Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients.Safety of mTOR inhibitors in adult solid organ transplantation.Phosphoinositide 3-Kinase-Dependent Signalling Pathways in Cutaneous Squamous Cell Carcinomas.Chemotherapy and Transplantation: The Role of Immunosuppression in Malignancy and a Review of Antineoplastic Agents in Solid Organ Transplant Recipients.The mTOR inhibitor rapamycin opposes carcinogenic changes to epidermal Akt1/PKBα isoform signaling.Skin cancer in immunosuppressed transplant patients: Vigilance matters.Revision of immunosuppression in a solid organ transplant recipient leads to complete remission of metastatic undifferentiated carcinomaProstate cancer characteristics and outcome in renal transplant recipients: results from a contemporary single center study.
P2860
Q26749011-3E1CD3C8-1501-4F67-A655-4E95F35487FAQ26772295-2F0F196F-EB57-4F03-9E78-C48E0367AF8CQ26798306-89D65D6C-DE6A-416D-A293-1CBCA7E5AA38Q26859216-899E1C3C-7FC4-4961-9CAF-E3454616919DQ33661124-D169EB24-0D79-482C-8801-24327E540CF0Q33829205-C995F477-A791-46DD-8BFB-11B9BE4BC010Q33923227-B5E78D44-F618-4D4A-805F-4DA8E7AA0CFEQ34268585-1CA7F18A-EE3A-4ACA-9F63-CD33988DCB4DQ35050810-974CBF9E-3A06-471A-8456-82D45481AEE9Q35607230-4D7C77C3-C462-43C3-B5AD-54B1E2E0E254Q36051817-B7CC82B0-88F2-495D-B4E8-4F3F472D67A9Q36087779-C290BEEF-57DA-4D58-BFA7-52C62C7C8F12Q36088854-BB32CBA9-49F5-4419-BB4A-708F26202650Q36456697-2055A98D-3F8B-4C4D-8C1D-756E38DC1965Q36528417-80DD48FF-FB3C-40B5-BE11-C08F23378210Q36610844-D53A4FC4-47D3-49E6-BA8E-93887F1F5D01Q36649878-123319C7-FE42-4102-9792-B2E44BE017CAQ36752004-6D7F3CFB-F96B-4E74-8C8D-6F4C03EDFA81Q36938488-4D6F30FA-377F-4122-BE48-CABD58340246Q37088225-1063D215-C99D-4F35-8F94-153F9F1E8A81Q37992135-E5601F49-20C3-43E8-A4BF-275DED671D0AQ38010633-71F027AB-E656-4AB4-A963-235AFBA81848Q38038696-693AC0AD-A201-4A35-A7DE-D92A5A748E90Q38125570-8FE886B1-E519-488B-8BE2-0D4620B7CE84Q38175673-F87B7914-9858-4479-BF9F-3E2A62BCB215Q38190678-754D875D-BF30-4BCE-869B-6BD351889A66Q38210623-59B92A71-4966-4B67-9ED7-28BC91ABDCD8Q38241710-A2CDBC1B-AF56-46F6-A1AF-74D588527033Q38311957-BA58F9AD-129D-49CD-8DB4-051BCC6398A6Q38328785-978F1CB1-6930-41E6-A3E1-F9369DA4EB20Q38533271-DD63A474-7F9B-4E3B-91B0-90FF1ED6578BQ38552310-DD29E71A-1C3C-477E-8CE6-FE01405DEDFDQ38668601-12BD5F61-9CDC-4ABA-A210-2507E1AA1F9AQ38669190-49626C28-7FD5-47EB-9B99-11C03DFF4911Q38684394-6F504CD0-7F64-44CF-BB0A-FB21D510435EQ38844500-C0A0AF21-8BBA-48B6-9685-A79FC34FF978Q39297991-6175F53E-C7EA-4701-B615-4981C92BD426Q39364043-5FABFF89-CC86-480E-B0DA-BEBBF29023AAQ39564761-CC60BCF5-6896-4505-B668-DDB462CA64F0Q39716989-F7C051C5-B3B3-4C56-AFA3-6ADA4DB7C40B
P2860
Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Lower malignancy rates in rena ...... esults from the CONVERT trial.
@en
Lower malignancy rates in rena ...... esults from the CONVERT trial.
@nl
type
label
Lower malignancy rates in rena ...... esults from the CONVERT trial.
@en
Lower malignancy rates in rena ...... esults from the CONVERT trial.
@nl
prefLabel
Lower malignancy rates in rena ...... esults from the CONVERT trial.
@en
Lower malignancy rates in rena ...... esults from the CONVERT trial.
@nl
P2093
P1433
P1476
Lower malignancy rates in rena ...... esults from the CONVERT trial.
@en
P2093
Eric S Maller
Francesco P Schena
Joan Korth-Bradley
John F Neylan
Josefina Alberú
Josep M Campistol
Maria Del Carmen Rial
Martin Polinsky
Michael D Pascoe
Robert Goldberg-Alberts
P304
P356
10.1097/TP.0B013E3182247AE2
P577
2011-08-01T00:00:00Z